Biotechnology News and Research

RSS

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration of Australia has approved KALYDECO (ivacaftor) for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

10 Jul 2013

Boehringer Ingelheim signs multi-year renewal agreement to NextBio Research Platform

NextBio, whose Big Data technology enables users to apply genomic data from disparate sources in novel and useful ways across life sciences research, today announced that Boehringer Ingelheim has signed a multi-year renewal agreement to the NextBio Research Platform.

9 Jul 2013

Viewpoints: Health care's hidden consensus; Examining the fee-for-service payment system; Alternative medicine's allure

The politicians' consensus is that health care reform shouldn't alter or disrupt the way the majority of Americans get their insurance today. ... The policy consensus, though, is that the status quo is actually the problem, and that it deserves to be threatened, undermined and replaced as expeditiously as possible. Wonks of the left and right disagree on what that replacement should look like. But they're united in regarding employer-provided coverage as an unsustainable relic (Ross Douthat, 7/6).

9 Jul 2013

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.

9 Jul 2013

Soligenix announces personalized medicine collaboration with SciClone

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942.

8 Jul 2013

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, announced today the publication of pre-clinical data for VB-201 in the journal of Atherosclerosis.

8 Jul 2013

Capricor to become wholly-owned subsidiary of Nile Therapeutics

Capricor, Inc., a privately held biotechnology company developing cardiac stem cell therapeutics to repair damaged heart muscle, and Nile Therapeutics, Inc. announced today that they have entered into a Merger Agreement under which Capricor will become a wholly-owned subsidiary of Nile Therapeutics, Inc. in an all-stock transaction.

8 Jul 2013

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Baxter International Inc. today announced data featuring ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], a leading recombinant treatment available worldwide, during the 24th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Amsterdam, The Netherlands.

From Baxter International Inc. 5 Jul 2013

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

Biogen Idec nd Swedish Orphan Biovitrum AB (publ) presented new data that support the clinical and safety profile of their long-lasting recombinant factor VIII candidate ELOCTATE for hemophilia A.

4 Jul 2013

Prana gets Austin HREC approval for 12-month open label extension study of PBT2 in Alzheimer’s patients

Prana Biotechnology today announced that it has received approval from the Austin Health Human Research Ethics Committee (HREC) to commence a 12-month open label extension study with Alzheimer’s Disease patients participating in Prana’s IMAGINE trial.

4 Jul 2013

Scientists uncover easy strategies to prevent harmful side-effects of antibiotics responses

A team of scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University has discovered why long-term treatment with many common antibiotics can cause harmful side effects-and they have uncovered two easy strategies that could help prevent these dangerous responses.

4 Jul 2013

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for obinutuzumab (GA101) and granted Priority Review for GA101 in the treatment of chronic lymphocytic leukemia, one of the most common forms of blood cancer, based on final Stage 1 data from the pivotal CLL11 trial.

3 Jul 2013

Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

Biogen Idec and Swedish Orphan Biovitrum AB (publ) today presented new findings for their long-lasting recombinant factor IX candidate ALPROLIX for hemophilia B at the XXIV International Society on Thrombosis and Haemostasis Congress in Amsterdam, The Netherlands.

3 Jul 2013

Gene therapy developed by UAB cures pediatric Sanfilippo Syndrome A in animal models

A single session of a gene therapy developed by the Universitat Autònoma de Barcelona (UAB) cures Sanfilippo Syndrome A in animal models. This syndrome is a neurodegenerative disease that affects between 1 and 9 out of every 100,000 children, and causes the death of the child on reaching adolescence.

3 Jul 2013

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

Array BioPharma Inc. announced today that a $5 million milestone was achieved after the start of Array's Phase 3 clinical trial in patients with low-grade serous ovarian cancer.

2 Jul 2013

West Pharmaceutical Services expands NovaGuard portfolio of needle safety products

West Pharmaceutical Services, Inc., a leading global developer and manufacturer of components and systems for injectable drug delivery, today announced the expansion of the NovaGuard portfolio of needle safety products.

2 Jul 2013

Bioline announces worldwide release of MyTaq Extract-PCR Kit

Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc., is proud to announce the worldwide release of the MyTaq Extract-PCR Kit.

2 Jul 2013

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from its RNAi therapeutic program for the treatment of hemophilia and rare bleeding disorders.

2 Jul 2013

UCLA researchers introduce gene therapy technique to treat sickle cell disease

Researchers at UCLA's Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research have successfully established the foundation for using hematopoietic (blood-producing) stem cells from the bone marrow of patients with sickle cell disease to treat the disease.

2 Jul 2013

Glide Pharma signs design optimisation agreement with Nypro Healthcare for solid dose injector

Glide Pharma today announced that it has entered an agreement with global device manufacturer Nypro Healthcare to complete the design optimisation of its solid dose injector in preparation for production scale up.

2 Jul 2013

Biotechnology News and Research

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Boehringer Ingelheim signs multi-year renewal agreement to NextBio Research Platform

Viewpoints: Health care's hidden consensus; Examining the fee-for-service payment system; Alternative medicine's allure

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Soligenix announces personalized medicine collaboration with SciClone

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

Capricor to become wholly-owned subsidiary of Nile Therapeutics

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

Prana gets Austin HREC approval for 12-month open label extension study of PBT2 in Alzheimer’s patients

Scientists uncover easy strategies to prevent harmful side-effects of antibiotics responses

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

Gene therapy developed by UAB cures pediatric Sanfilippo Syndrome A in animal models

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

West Pharmaceutical Services expands NovaGuard portfolio of needle safety products

Bioline announces worldwide release of MyTaq Extract-PCR Kit

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

UCLA researchers introduce gene therapy technique to treat sickle cell disease

Glide Pharma signs design optimisation agreement with Nypro Healthcare for solid dose injector

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News